Afghanistan vs Central African Republic: Average cost of multi drug-resistant tuberculosis treatment
Afghanistan
1,000 constant 2022 US$
in 2024
Central African Republic
1,043 constant 2022 US$
in 2024
Afghanistan rank
48th
Central African Republic rank
46th
Average cost of multi drug-resistant tuberculosis treatment over time
- Afghanistan
- Central African Republic
How they compare
Central African Republic currently reports 1,043 constant 2022 US$ against 1,000 constant 2022 US$ in Afghanistan, a difference of 43 constant 2022 US$.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Central African Republic ahead.
Afghanistan ranks 48th and Central African Republic ranks 46th of 92 countries.
Central African Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Central African Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,300 constant 2022 US$ | 1,461 constant 2022 US$ | 161.33 constant 2022 US$ | Central African Republic |
| 2020s | 1,000 constant 2022 US$ | 1,080 constant 2022 US$ | 80.25 constant 2022 US$ | Central African Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Afghanistan or Central African Republic?
- Central African Republic, at 1,043 constant 2022 US$ against 1,000 constant 2022 US$ in Afghanistan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Afghanistan and Central African Republic?
- 43 constant 2022 US$, with Central African Republic ahead.
- How many years of comparable data are there for Afghanistan and Central African Republic?
- 7 years are reported by both, from 2017 to 2024.
- How do Afghanistan and Central African Republic rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Afghanistan ranks 48th and Central African Republic ranks 46th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.